Abstract
Background: The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but there are few data on their effectiveness when used together. We compared the effects of SFC 50/500 μg twice daily in addition to TIO 18 μg once daily with the individual treatments alone. Methods: 41 patients with COPD participated in a randomised, double blind, double dummy, three way crossover study with 2 week washout periods between treatments. Lung function assessment included plethysmography and spirometry. The primary end point was post-dose specific airways conductance (sGaw) area under the curve (AUC0-4 h) on day 14. Results: AUC0_4 h sGaw was significantly higher on day 14 after SFC+TIO compared with TIO (22%) or SFC alone (27%) (both p
Original language | English |
---|---|
Pages (from-to) | 592-598 |
Number of pages | 6 |
Journal | Thorax |
Volume | 63 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2008 |
Fingerprint
Dive into the research topics of 'Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD'. Together they form a unique fingerprint.Impacts
-
Clinical trials in chronic obstructive pulmonary disease (COPD) advancing effective combination treatments
Singh, S. (Participant) & Vestbo, J. (Participant)
Impact: Health and wellbeing, Economic
-
Definitive multinational efficacy trials and pioneering ‘real-world’ evidence informing treatments and international strategy for managing chronic obstructive pulmonary disease (COPD)
Vestbo, J. (Participant), Singh, S. (Participant) & (Participant)
Impact: Health and wellbeing
-
Development and application of inhaled therapies in airway diseases
(Participant), Vestbo, J. (Participant), Singh, S. (Participant) & (Participant)
Impact: Health impacts